back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Recent filings | ||||||
| Filed 2024-04-16 18:20 Tx date 2024-04-16 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-228,388.8272
-22,222 vol $10.28 each |
0 | |
| Filed 2024-04-16 18:20 Tx date 2024-04-15 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-228,793.2676
-22,222 vol $10.30 each |
0 | |
| Filed 2024-04-16 18:18 Tx date 2024-04-16 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$51,332
+22,222 vol $2.31 each |
22,222 | |
| Filed 2024-04-16 18:17 Tx date 2024-04-15 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$51,332
+22,222 vol $2.31 each |
22,222 | |
| Filed 2024-04-16 18:16 Tx date 2014-04-28 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-04-16 18:15 Tx date 2024-04-16 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
5 - Senior Officer of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
$-51,332.82
-22,222 vol $2.31 each |
449,135 | |
| Filed 2024-04-16 18:14 Tx date 2024-04-15 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
5 - Senior Officer of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
$-51,332.82
-22,222 vol $2.31 each |
471,357 | |
| Older filings | ||||||
| Filed 2024-04-15 18:11 Tx date 2024-04-15 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-8,360
-800 vol $10.45 each |
49,278 | |
| Filed 2024-04-15 18:10 Tx date 2024-04-15 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,000
+1,389 vol $3.60 each |
50,078 | |
| Filed 2024-04-15 18:09 Tx date 2024-04-15 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
$-5,000.40
-1,389 vol $3.60 each |
200,679 | |
| Filed 2024-04-03 12:16 Tx date 2024-04-01 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
+12,500 vol |
161,271 | |
| Filed 2024-04-03 12:15 Tx date 2024-04-01 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
+29,167 vol |
2,531,348 | |
| Filed 2024-04-03 12:13 Tx date 2024-04-01 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
56 - Grant of rights
|
+12,500 vol |
||
| Filed 2024-03-29 16:54 Tx date 2024-03-26 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-23,190.58
-2,114 vol $10.97 each |
48,689 | |
| Filed 2024-03-29 16:53 Tx date 2024-03-26 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$9,999
+4,329 vol $2.31 each |
50,803 | |
| Filed 2024-03-29 16:52 Tx date 2024-03-26 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
$-9,999.99
-4,329 vol $2.31 each |
202,068 | |
| Filed 2024-03-29 16:48 Tx date 2024-03-26 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-152,345.6675
-13,975 vol $10.90 each |
148,771 | |
| Filed 2024-03-29 16:47 Tx date 2024-03-25 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-153,690.0625
-13,975 vol $11.00 each |
162,746 | |
| Filed 2023-12-29 13:02 Tx date 2023-12-28 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-42,226.80
-3,656 vol $11.55 each |
2,502,181 | |
| Filed 2023-12-29 12:57 Tx date 2023-12-28 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$13,578
+8,540 vol $1.59 each |
2,505,837 | |
| Filed 2023-12-29 12:56 Tx date 2023-12-28 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
$-13,578.60
-8,540 vol $1.59 each |
21,348,663 | |
| Filed 2023-12-29 12:46 Tx date 2023-12-26 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-15,151
-1,390 vol $10.90 each |
46,474 | |
| Filed 2023-12-29 12:45 Tx date 2023-12-26 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,998
+3,144 vol $1.59 each |
47,864 | |
| Filed 2023-12-29 12:44 Tx date 2023-12-26 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
$-4,998.96
-3,144 vol $1.59 each |
206,397 | |
| Filed 2023-11-27 14:15 Tx date 2023-11-24 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,219.25
-269 vol $8.25 each |
44,720 | |
| Filed 2023-11-16 16:00 Tx date 2023-11-16 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$50,000
+20,492 vol $2.44 each |
213,825 | |
| Filed 2023-11-16 15:58 Tx date 2023-11-16 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$307,999
+133,333 vol $2.31 each |
133,333 | |
| Filed 2023-11-16 15:56 Tx date 2014-04-28 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-11-16 15:47 Tx date 2023-11-16 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
$-50,000.48
-20,492 vol $2.44 each |
175,000 | |
| Filed 2023-11-16 15:46 Tx date 2023-11-16 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
$-56,500
-50,000 vol $1.13 each |
195,492 | |
| Filed 2023-11-16 15:45 Tx date 2023-11-16 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
$-26,900
-10,000 vol $2.69 each |
245,492 | |
| Filed 2023-11-16 15:44 Tx date 2023-11-16 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
$-307,999.23
-133,333 vol $2.31 each |
255,492 | |
| Filed 2023-11-03 17:18 Tx date 2023-11-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$118,920
+74,793 vol $1.59 each |
2,497,297 | |
| Filed 2023-11-03 17:17 Tx date 2023-11-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
$-118,920.87
-74,793 vol $1.59 each |
21,357,203 | |
| Filed 2023-08-22 17:29 Tx date 2023-08-18 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-5,283.05
-673 vol $7.85 each |
44,989 | |
| Filed 2023-08-07 09:11 Tx date 2023-08-07 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$1,605,999
+200,000 vol $8.03 each |
493,579 | |
| Filed 2023-07-24 17:03 Tx date 2023-07-24 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-55,523.32
-6,796 vol $8.17 each |
45,662 | |
| Filed 2023-07-24 17:01 Tx date 2023-07-24 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$11,999
+16,666 vol $0.72 each |
52,458 | |
| Filed 2023-07-24 17:00 Tx date 2023-07-24 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
$-11,999.52
-16,666 vol $0.72 each |
209,541 | |
| Filed 2023-07-06 17:28 Tx date 2023-07-06 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-18,693.29
-2,207 vol $8.47 each |
35,792 | |
| Filed 2023-07-06 17:27 Tx date 2023-07-06 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$4,999
+5,208 vol $0.96 each |
37,999 | |
| Filed 2023-07-06 17:25 Tx date 2023-07-06 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-4,999.68
-5,208 vol $0.96 each |
226,207 | |
| Filed 2023-07-06 17:23 Tx date 2023-07-06 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
$-4,999.68
-5,208 vol $0.96 each |
||
| Filed 2023-07-05 16:37 Tx date 2023-06-30 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-66,150
-7,500 vol $8.82 each |
176,721 | |
| Filed 2023-07-05 16:36 Tx date 2023-06-30 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-67,275
-7,500 vol $8.97 each |
184,221 | |
| Filed 2023-07-05 16:35 Tx date 2023-06-30 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-89,900
-10,000 vol $8.99 each |
191,721 | |
| Filed 2023-07-05 16:35 Tx date 2023-06-30 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$61,250
+25,000 vol $2.45 each |
201,721 | |
| Filed 2023-07-05 16:32 Tx date 2023-06-30 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-61,250
-25,000 vol $2.45 each |
680,000 | |
| Filed 2023-06-13 10:32 Tx date 2023-06-12 |
$FRX
Fennec Pharmaceuticals Inc. |
Jodi, Cook
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$175,600
+20,000 vol $8.78 each |
100,000 | |
| Filed 2023-06-13 10:29 Tx date 2023-06-12 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$175,600
+20,000 vol $8.78 each |
231,415 | |
| Filed 2023-06-13 10:27 Tx date 2023-06-12 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$219,499
+25,000 vol $8.78 each |
388,825 | |
| Filed 2023-06-13 10:25 Tx date 2023-06-12 |
$FRX
Fennec Pharmaceuticals Inc. |
Brughera, Marco
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$175,600
+20,000 vol $8.78 each |
175,545 | |
| Filed 2023-06-13 10:20 Tx date 2023-06-12 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$175,600
+20,000 vol $8.78 each |
293,579 | |
| Filed 2023-04-28 17:03 Tx date 2023-04-28 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$1,456,000
+175,000 vol $8.32 each |
21,431,996 | |
| Filed 2023-04-28 16:58 Tx date 2023-04-28 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$624,000
+75,000 vol $8.32 each |
705,000 | |
| Filed 2023-04-28 16:54 Tx date 2023-04-28 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-7,639.44
-916 vol $8.34 each |
32,791 | |
| Filed 2023-04-28 16:52 Tx date 2023-04-28 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$4,998
+1,700 vol $2.94 each |
33,707 | |
| Filed 2023-04-28 16:49 Tx date 2023-04-28 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-4,998
-1,700 vol $2.94 each |
211,415 | |
| Filed 2023-04-04 08:56 Tx date 2023-03-31 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$1,456,000
+175,000 vol $8.32 each |
21,256,996 | |
| Filed 2023-04-04 08:49 Tx date 2023-03-31 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$624,083
+75,010 vol $8.32 each |
630,000 | |
| Filed 2023-03-03 17:29 Tx date 2023-03-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-19,788.93
-2,177 vol $9.09 each |
32,007 | |
| Filed 2023-03-03 17:28 Tx date 2023-03-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
+4,166 vol |
34,184 | |
| Filed 2023-03-03 17:26 Tx date 2023-03-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
+4,166 vol |
||
| Filed 2023-03-03 17:24 Tx date 2023-03-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-9,998.40
-4,166 vol $2.40 each |
213,115 | |
| Filed 2023-03-03 17:22 Tx date 2023-03-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
+4,166 vol |
||
| Filed 2023-03-03 17:20 Tx date 2023-03-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$9,998
+4,166 vol $2.40 each |
||
| Filed 2022-11-17 15:30 Tx date 2022-11-17 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-2,660.67
-333 vol $7.99 each |
30,018 | |
| Filed 2022-10-20 17:23 Tx date 2022-10-20 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
+4,762 vol |
30,351 | |
| Filed 2022-10-20 17:22 Tx date 2022-10-20 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-17,081.68
-2,068 vol $8.26 each |
25,589 | |
| Filed 2022-10-20 17:18 Tx date 2022-10-20 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
$-5,000.10
-4,762 vol $1.05 each |
217,281 | |
| Filed 2022-09-22 11:51 Tx date 2022-09-21 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-162,704.08
-19,052 vol $8.54 each |
176,721 | |
| Filed 2022-09-15 11:51 Tx date 2022-09-12 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$11,999
+16,666 vol $0.72 each |
2,422,504 | |
| Filed 2022-09-15 10:18 Tx date 2022-09-12 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
10 - Acquisition or disposition in the public market
|
$-11,999.52
-16,666 vol $0.72 each |
21,081,996 | |
| Filed 2022-08-24 11:05 Tx date 2022-08-22 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$52,500
+50,000 vol $1.05 each |
2,405,838 | |
| Filed 2022-08-24 11:04 Tx date 2022-08-22 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$52,500
+50,000 vol $1.05 each |
21,098,662 | |
| Filed 2022-07-18 17:45 Tx date 2022-07-18 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-29,339.30
-4,379 vol $6.70 each |
27,657 | |
| Filed 2022-07-18 17:43 Tx date 2022-07-18 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,999
+11,111 vol $0.45 each |
32,036 | |
| Filed 2022-07-18 17:39 Tx date 2022-07-18 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$4,999
+11,111 vol $0.45 each |
222,043 | |
| Filed 2022-06-16 09:45 Tx date 2022-06-14 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$111,800
+20,000 vol $5.59 each |
210,932 | |
| Filed 2022-06-16 09:43 Tx date 2022-06-14 |
$FRX
Fennec Pharmaceuticals Inc. |
Jodi, Cook
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$111,800
+20,000 vol $5.59 each |
80,000 | |
| Filed 2022-06-16 09:41 Tx date 2022-06-14 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$139,750
+25,000 vol $5.59 each |
363,825 | |
| Filed 2022-06-16 09:40 Tx date 2022-06-14 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$111,800
+20,000 vol $5.59 each |
273,579 | |
| Filed 2022-06-16 09:37 Tx date 2022-06-14 |
$FRX
Fennec Pharmaceuticals Inc. |
Brughera, Marco
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$111,800
+20,000 vol $5.59 each |
155,545 | |
| Filed 2022-03-09 15:53 Tx date 2022-03-09 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,999
+9,259 vol $0.54 each |
20,925 | |
| Filed 2022-03-09 15:52 Tx date 2022-03-09 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,999
+8,333 vol $0.60 each |
11,666 | |
| Filed 2022-03-08 11:35 Tx date 2022-03-08 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-4,999.86
-9,259 vol $0.54 each |
190,932 | |
| Filed 2022-03-08 11:31 Tx date 2022-03-08 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
-8,333 vol |
200,191 | |
| Filed 2021-12-20 17:57 Tx date 2021-12-20 |
$FRX
Fennec Pharmaceuticals Inc. |
Goel, Shubh
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
56 - Grant of rights
|
+37,500 vol |
37,500 | |
| Filed 2021-12-20 17:56 Tx date 2019-09-09 |
$FRX
Fennec Pharmaceuticals Inc. |
Goel, Shubh
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-12-20 17:53 Tx date 2021-12-20 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
56 - Grant of rights
|
+37,500 vol |
195,773 | |
| Filed 2021-12-20 17:39 Tx date 2021-12-20 |
$FRX
Fennec Pharmaceuticals Inc. |
Goel, Shubh
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$306,000
+75,000 vol $4.08 each |
375,000 | |
| Filed 2021-12-20 17:35 Tx date 2021-12-20 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$1,224,000
+300,000 vol $4.08 each |
21,048,662 | |
| Filed 2021-12-20 17:30 Tx date 2015-11-12 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-12-20 17:29 Tx date 2015-11-12 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-12-20 17:27 Tx date 2015-11-12 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-12-20 17:19 Tx date 2015-11-12 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-12-20 17:15 Tx date 2021-12-20 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$306,000
+75,000 vol $4.08 each |
554,990 | |
| Filed 2021-10-28 09:39 Tx date 2021-10-26 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-4,999.50
-3,333 vol $1.50 each |
208,524 | |
| Filed 2021-10-28 09:35 Tx date 2021-10-26 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$4,999
+3,333 vol $1.50 each |
3,333 | |
| Filed 2021-10-28 09:31 Tx date 2011-08-25 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-06-30 16:47 Tx date 2021-06-29 |
$FRX
Fennec Pharmaceuticals Inc. |
Jodi, Cook
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$150,400
+20,000 vol $7.52 each |
60,000 | |
| Filed 2021-06-30 16:45 Tx date 2021-06-29 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$150,400
+20,000 vol $7.52 each |
211,857 | |
| Filed 2021-06-30 16:42 Tx date 2021-06-29 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$188,000
+25,000 vol $7.52 each |
338,825 | |
| Filed 2021-06-30 16:40 Tx date 2021-06-29 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$150,400
+20,000 vol $7.52 each |
253,579 | |
| Filed 2021-06-30 16:37 Tx date 2021-06-29 |
$FRX
Fennec Pharmaceuticals Inc. |
Brughera, Marco
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$150,400
+20,000 vol $7.52 each |
135,545 | |
| Filed 2021-06-03 08:55 Tx date 2021-06-02 |
$FRX
Fennec Pharmaceuticals Inc. |
Goel, Shubh
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$753,000
+100,000 vol $7.53 each |
300,000 | |
| Filed 2021-06-03 08:48 Tx date 2021-06-02 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$1,882,500
+250,000 vol $7.53 each |
20,748,662 | |
| Filed 2021-06-03 08:45 Tx date 2021-06-02 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$753,000
+100,000 vol $7.53 each |
479,990 | |
| Filed 2020-08-17 16:49 Tx date 2020-08-17 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-69,051.03
-12,093 vol $5.71 each |
2,355,838 | |
| Filed 2020-08-17 16:49 Tx date 2020-08-14 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-215,913.84
-38,013 vol $5.68 each |
2,367,931 | |
| Filed 2020-08-17 16:48 Tx date 2020-08-13 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-218,861.87
-37,931 vol $5.77 each |
2,405,944 | |
| Filed 2020-08-17 16:47 Tx date 2020-08-13 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-599,329.12
-97,136 vol $6.17 each |
2,443,875 | |
| Filed 2020-08-17 16:46 Tx date 2020-08-13 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$599,327
+323,961 vol $1.85 each |
2,541,011 | |
| Filed 2020-08-17 16:44 Tx date 2020-08-17 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-73,510.54
-12,874 vol $5.71 each |
158,273 | |
| Filed 2020-08-17 16:43 Tx date 2020-08-14 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-220,952
-38,900 vol $5.68 each |
171,147 | |
| Filed 2020-08-17 16:41 Tx date 2020-08-13 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-224,037.56
-38,828 vol $5.77 each |
210,047 | |
| Filed 2020-08-17 16:39 Tx date 2020-08-13 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-599,329.12
-97,136 vol $6.17 each |
248,875 | |
| Filed 2020-08-17 16:38 Tx date 2020-08-13 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$599,327
+323,961 vol $1.85 each |
346,011 | |
| Filed 2020-08-14 09:03 Tx date 2020-08-13 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$123,400
+20,000 vol $6.17 each |
191,857 | |
| Filed 2020-08-14 08:44 Tx date 2020-08-13 |
$FRX
Fennec Pharmaceuticals Inc. |
Jodi, Cook
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$123,400
+20,000 vol $6.17 each |
40,000 | |
| Filed 2020-08-14 08:41 Tx date 2020-08-13 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$154,250
+25,000 vol $6.17 each |
313,825 | |
| Filed 2020-08-14 08:39 Tx date 2020-08-13 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$123,400
+20,000 vol $6.17 each |
233,579 | |
| Filed 2020-08-14 08:37 Tx date 2020-08-13 |
$FRX
Fennec Pharmaceuticals Inc. |
Brughera, Marco
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$123,400
+20,000 vol $6.17 each |
115,545 | |
| Filed 2020-08-14 08:07 Tx date 2020-08-13 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-764,547.96
-323,961 vol $2.36 each |
20,498,662 | |
| Filed 2020-08-14 08:02 Tx date 2020-08-13 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-764,547.96
-323,961 vol $2.36 each |
379,990 | |
| Filed 2020-05-15 17:55 Tx date 2020-05-15 |
$FRX
Fennec Pharmaceuticals Inc. |
Goel, Shubh
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$173,250
+25,000 vol $6.93 each |
200,000 | |
| Filed 2020-05-15 17:47 Tx date 2020-05-15 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$866,250
+125,000 vol $6.93 each |
703,951 | |
| Filed 2020-05-15 17:44 Tx date 2020-05-15 |
$FRX
Fennec Pharmaceuticals Inc. |
Goel, Shubh
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$173,250
+25,000 vol $6.93 each |
||
| Filed 2020-05-15 17:41 Tx date 2020-05-15 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$1,732,500
+250,000 vol $6.93 each |
20,822,623 | |
| Filed 2020-05-06 19:05 Tx date 2020-05-04 |
$FRX
Fennec Pharmaceuticals Inc. |
Southpoint Capital Advisors LP
3 - 10% Security Holder of Issuer
Holder: Southpoint Master Fund LP (Indirect Ownership)
|
Common Shares
15 - Acquisition or disposition under a prospectus
|
$500,000
+80,000 vol $6.25 each |
4,077,214 | |
| Filed 2019-11-15 09:20 Tx date 2019-11-13 |
$FRX
Fennec Pharmaceuticals Inc. |
Jodi, Cook
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$108,000
+20,000 vol $5.40 each |
20,000 | |
| Filed 2019-09-23 13:32 Tx date 2019-09-23 |
$FRX
Fennec Pharmaceuticals Inc. |
Jodi, Cook
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-09-10 16:56 Tx date 2019-09-09 |
$FRX
Fennec Pharmaceuticals Inc. |
Goel, Shubh
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$829,500
+175,000 vol $4.74 each |
175,000 | |
| Filed 2019-09-10 16:54 Tx date 2019-09-09 |
$FRX
Fennec Pharmaceuticals Inc. |
Goel, Shubh
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-09-10 16:53 Tx date 2019-09-09 |
$FRX
Fennec Pharmaceuticals Inc. |
Goel, Shubh
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-09-10 16:32 Tx date 2019-09-09 |
$FRX
Fennec Pharmaceuticals Inc. |
Goel, Shubh
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-06-19 13:04 Tx date 2019-06-18 |
$FRX
Fennec Pharmaceuticals Inc. |
Brughera, Marco
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$85,200
+20,000 vol $4.26 each |
95,545 | |
| Filed 2019-06-19 12:55 Tx date 2019-06-18 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$85,200
+20,000 vol $4.26 each |
171,857 | |
| Filed 2019-06-19 12:50 Tx date 2019-06-18 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$85,200
+20,000 vol $4.26 each |
213,579 | |
| Filed 2019-06-19 12:47 Tx date 2019-06-18 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$106,500
+25,000 vol $4.26 each |
288,825 | |
| Filed 2019-04-06 09:58 Tx date 2019-04-04 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$724,500
+150,000 vol $4.83 each |
20,572,623 | |
| Filed 2019-04-06 09:54 Tx date 2019-04-04 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$386,400
+80,000 vol $4.83 each |
578,951 | |
| Filed 2018-08-21 Tx date 2018-08-20 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-24,552
-17,050 vol $1.44 each |
20,422,623 | |
| Filed 2018-08-21 Tx date 2018-08-20 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$24,552
+17,050 vol $1.44 each |
2,217,050 | |
| Filed 2018-08-17 Tx date 2018-08-15 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$24,552
+17,050 vol $1.44 each |
22,050 | |
| Filed 2018-08-17 Tx date 2018-08-15 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-24,552
-17,050 vol $1.44 each |
498,951 | |
| Filed 2018-06-10 Tx date 2018-06-08 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$218,600
+20,000 vol $10.93 each |
193,579 | |
| Filed 2018-06-10 Tx date 2018-06-08 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$218,600
+20,000 vol $10.93 each |
151,857 | |
| Filed 2018-06-10 Tx date 2018-06-08 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$273,250
+25,000 vol $10.93 each |
263,825 | |
| Filed 2018-06-10 Tx date 2018-06-08 |
$FRX
Fennec Pharmaceuticals Inc. |
Brughera, Marco
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$218,600
+20,000 vol $10.93 each |
75,545 | |
| Filed 2018-02-07 Tx date 2018-02-06 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$419,000
+50,000 vol $8.38 each |
516,001 | |
| Filed 2018-02-07 Tx date 2018-02-06 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$838,000
+100,000 vol $8.38 each |
20,439,673 | |
| Filed 2017-12-13 Tx date 2017-12-12 |
$FRX
Fennec Pharmaceuticals Inc. |
Essetifin S.p.a.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,499,977
+294,115 vol $8.50 each |
3,225,694 | |
| Filed 2017-06-28 Tx date 2017-06-27 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$102,000
+20,000 vol $5.10 each |
173,579 | |
| Filed 2017-06-28 Tx date 2017-06-27 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$254,999
+50,000 vol $5.10 each |
466,001 | |
| Filed 2017-06-28 Tx date 2017-06-27 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$127,499
+25,000 vol $5.10 each |
238,825 | |
| Filed 2017-06-28 Tx date 2017-06-27 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$102,000
+20,000 vol $5.10 each |
131,857 | |
| Filed 2017-06-28 Tx date 2017-06-27 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$509,999
+100,000 vol $5.10 each |
20,339,673 | |
| Filed 2017-06-28 Tx date 2017-06-27 |
$FRX
Fennec Pharmaceuticals Inc. |
Brughera, Marco
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$102,000
+20,000 vol $5.10 each |
55,545 | |
| Filed 2017-06-09 Tx date 2017-06-08 |
$FRX
Fennec Pharmaceuticals Inc. |
Essetifin S.p.a.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$1,200,000
+300,000 vol $4.00 each |
2,931,579 | |
| Filed 2017-01-03 Tx date 2016-08-10 |
$FRX
Fennec Pharmaceuticals Inc. |
Brughera, Marco
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-01-03 Tx date 2016-08-10 |
$FRX
Fennec Pharmaceuticals Inc. |
Brughera, Marco
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-01-03 Tx date 2016-12-30 |
$FRX
Fennec Pharmaceuticals Inc. |
Brughera, Marco
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$74,999
+35,545 vol $2.11 each |
35,545 | |
| Filed 2016-07-08 Tx date 2016-07-05 |
$FRX
Fennec Pharmaceuticals Inc. |
Raykov, Rostislav Christov
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$367,500
+150,000 vol $2.45 each |
20,239,673 | |
| Filed 2016-07-08 Tx date 2016-07-05 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$183,750
+75,000 vol $2.45 each |
416,001 | |
| Filed 2016-06-10 Tx date 2016-06-09 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$50,000
+20,492 vol $2.44 each |
213,825 | |
| Filed 2016-06-10 Tx date 2016-06-09 |
$FRX
Fennec Pharmaceuticals Inc. |
Skolsky, Steven
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$9,999
+4,098 vol $2.44 each |
88,701 | |
| Filed 2016-06-10 Tx date 2016-06-09 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$34,999
+14,344 vol $2.44 each |
111,857 | |
| Filed 2016-06-10 Tx date 2016-06-09 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$25,000
+10,246 vol $2.44 each |
153,579 | |
| Filed 2016-05-17 Tx date 2016-05-16 |
$FRX
Fennec Pharmaceuticals Inc. |
Essetifin S.p.a.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
1,092,828 | ||
| Filed 2016-05-17 Tx date 2016-05-16 |
$FRX
Fennec Pharmaceuticals Inc. |
Essetifin S.p.a.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$2,923,626
+1,538,751 vol $1.90 each |
2,631,579 | |
| Filed 2015-12-16 Tx date 2015-12-11 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$56,499
+50,000 vol $1.13 each |
193,333 | |
| Filed 2015-11-19 Tx date 2015-11-12 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
700,000 | ||
| Filed 2015-11-18 Tx date 2015-11-12 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
5,000 | ||
| Filed 2015-11-18 Tx date 2015-11-12 |
$FRX
Fennec Pharmaceuticals Inc. |
Andrade, Robert Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
341,001 | ||
| Filed 2015-11-17 Tx date 2015-11-16 |
$FRX
Fennec Pharmaceuticals Inc. |
Skolsky, Steven
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$4,996
+4,062 vol $1.23 each |
84,603 | |
| Filed 2015-11-17 Tx date 2015-11-16 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$4,996
+4,062 vol $1.23 each |
97,513 | |
| Filed 2015-08-18 Tx date 2015-08-14 |
$FRX
Fennec Pharmaceuticals Inc. |
Lynes, Krysia Laura
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$5,414
+3,342 vol $1.62 each |
3,342 | |
| Filed 2015-08-18 Tx date 2015-08-14 |
$FRX
Fennec Pharmaceuticals Inc. |
Lynes, Krysia Laura
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-5,414.04
-3,342 vol $1.62 each |
41,177 | |
| Filed 2015-08-18 Tx date 2013-08-15 |
$FRX
Fennec Pharmaceuticals Inc. |
Lynes, Krysia Laura
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2015-08-04 Tx date 2015-08-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Skolsky, Steven
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$4,998
+2,127 vol $2.35 each |
80,541 | |
| Filed 2015-08-04 Tx date 2015-08-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$4,998
+2,127 vol $2.35 each |
93,451 | |
| Filed 2015-05-18 Tx date 2014-08-04 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$4,999
+5,376 vol $0.93 each |
225,608 | |
| Filed 2015-05-18 Tx date 2014-09-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Lynes, Krysia Laura
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-89,048 vol |
44,519 | |
| Filed 2015-05-18 Tx date 2014-09-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-150,409 vol |
75,199 | |
| Filed 2015-05-18 Tx date 2014-11-07 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$4,998
+1,960 vol $2.55 each |
77,159 | |
| Filed 2015-05-18 Tx date 2014-12-31 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$26,900
+10,000 vol $2.69 each |
87,159 | |
| Filed 2015-05-18 Tx date 2015-03-16 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$4,999
+1,992 vol $2.51 each |
89,151 | |
| Filed 2015-05-18 Tx date 2015-05-11 |
$FRX
Fennec Pharmaceuticals Inc. |
Rallis, Chris Anigeron
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$4,997
+2,173 vol $2.30 each |
91,324 | |
| Filed 2015-05-18 Tx date 2014-09-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Skolsky, Steven
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-124,590 vol |
62,289 | |
| Filed 2015-05-18 Tx date 2014-11-07 |
$FRX
Fennec Pharmaceuticals Inc. |
Skolsky, Steven
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$4,998
+1,960 vol $2.55 each |
64,249 | |
| Filed 2015-05-18 Tx date 2014-12-31 |
$FRX
Fennec Pharmaceuticals Inc. |
Skolsky, Steven
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$26,900
+10,000 vol $2.69 each |
74,249 | |
| Filed 2015-05-18 Tx date 2015-03-16 |
$FRX
Fennec Pharmaceuticals Inc. |
Skolsky, Steven
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$4,999
+1,992 vol $2.51 each |
76,241 | |
| Filed 2015-05-18 Tx date 2015-05-11 |
$FRX
Fennec Pharmaceuticals Inc. |
Skolsky, Steven
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$4,997
+2,173 vol $2.30 each |
||
| Filed 2015-05-18 Tx date 2015-05-11 |
$FRX
Fennec Pharmaceuticals Inc. |
Skolsky, Steven
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$4,997
+2,173 vol $2.30 each |
78,414 | |
| Filed 2015-05-14 Tx date 2014-12-31 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$26,900
+10,000 vol $2.69 each |
143,333 | |
| Filed 2015-05-14 Tx date 2014-09-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Islam, Khalid
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-266,667 vol |
133,333 | |
| Filed 2015-05-13 Tx date 2014-09-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-266,667 vol |
133,333 | |
| Filed 2015-05-13 Tx date 2014-12-31 |
$FRX
Fennec Pharmaceuticals Inc. |
Haigh, Adrian J.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$26,900
+10,000 vol $2.69 each |
143,333 | |
| Filed 2015-05-04 Tx date 2014-07-29 |
$FRX
Fennec Pharmaceuticals Inc. |
Southpoint Capital Advisors LP
3 - 10% Security Holder of Issuer
Holder: Southpoint Master Fund LP (Control or Direction)
|
Warrants (Common Shares)
36 - Conversion or exchange
|
$-12,679,680
-158,496,000 vol $0.08 each |
0 | |
| Filed 2015-05-04 Tx date 2010-02-21 |
$FRX
Fennec Pharmaceuticals Inc. |
Southpoint Capital Advisors LP
3 - 10% Security Holder of Issuer
Holder: Southpoint Master Fund LP (Control or Direction)
|
Warrants (Common Shares)
55 - Expiration of warrants
|
$-8,300,800
-20,752,000 vol $0.40 each |
0 | |
| Filed 2015-05-04 Tx date 2015-04-29 |
$FRX
Fennec Pharmaceuticals Inc. |
Southpoint Capital Advisors LP
3 - 10% Security Holder of Issuer
Holder: Southpoint Master Fund LP (Control or Direction)
|
Common Shares
54 - Exercise of warrants
|
$440,266
+293,511 vol $1.50 each |
3,997,214 | |
| Filed 2015-05-04 Tx date 2011-08-25 |
$FRX
Fennec Pharmaceuticals Inc. |
Southpoint Capital Advisors LP
3 - 10% Security Holder of Issuer
Holder: Southpoint Master Fund LP (Control or Direction)
|
Common Shares
37 - Stock split or consolidation
|
-188,888,889 vol |
11,111,111 | |
| Filed 2015-05-04 Tx date 2014-09-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Southpoint Capital Advisors LP
3 - 10% Security Holder of Issuer
Holder: Southpoint Master Fund LP (Control or Direction)
|
Common Shares
37 - Stock split or consolidation
|
-7,407,408 vol |
3,703,703 | |
| Filed 2015-05-04 Tx date 2015-04-28 |
$FRX
Fennec Pharmaceuticals Inc. |
Southpoint Capital Advisors LP
3 - 10% Security Holder of Issuer
Holder: Southpoint Master Fund LP (Control or Direction)
|
Warrants (Common Shares)
54 - Exercise of warrants
|
$-440,266.50
-293,511 vol $1.50 each |
0 | |
| Filed 2015-05-04 Tx date 2014-09-03 |
$FRX
Fennec Pharmaceuticals Inc. |
Southpoint Capital Advisors LP
3 - 10% Security Holder of Issuer
Holder: Southpoint Master Fund LP (Control or Direction)
|
Warrants (Common Shares)
37 - Stock split or consolidation
|
$-880,533
-587,022 vol $1.50 each |
293,511 | |
| Filed 2015-05-04 Tx date 2014-07-29 |
$FRX
Fennec Pharmaceuticals Inc. |
Southpoint Capital Advisors LP
3 - 10% Security Holder of Issuer
Holder: Southpoint Master Fund LP (Control or Direction)
|
Warrants (Common Shares)
36 - Conversion or exchange
|
$440,266
+880,533 vol $0.50 each |
880,533 | |